COVID-19 update

This item appears on page 5 of the September 2021 issue.
This is subscriber only post.
Get one year of online-only access — only $15!
Below is a sample of the article.
Please login or subscribe to ITN to read the entire post.

If you would like to read an issue from the archives that is free to nonsubscribers click here.

At press time, active COVID-19 infections had been confirmed in 192 countries and territories, with more than 198.5 million cases and, resulting from those, more than 4.2 million deaths.

The Delta variant of COVID-19, which is more infectious than other variants, is becoming the dominant variant around the world. Almost every country saw a significant spike in new cases in July. The daily average of new cases over a 2-week period rose more than 100% in most of Europe, Africa and the Americas. However, in countries with robust vaccine programs, the 2-week daily averages of new hospitalizations and deaths rose at much smaller rates, usually less than 50%.

Most vaccines used around the world, including the Pfizer, Moderna and Johnson & Johnson vaccines approved in the US, have shown significant protection against severe symptoms from the Delta variant. Though the Delta variant has caused breakthrough infections in vaccinated people at a higher rate than other variants, that number still amounts to less than 1% of all vaccinated people. Worldwide, almost all hospitalizations and deaths since June 1 have occurred among non-vaccinated people.

Please login or subscribe to ITN to read the entire post.

At press time, active COVID-19 infections had been confirmed in 192 countries and territories, with more than 198.5 million cases and, resulting from those, more than 4.2 million deaths.

The Delta variant of COVID-19, which is more infectious than other variants, is becoming the dominant variant around the world. Almost every country saw a significant spike in new cases in July. The daily average of new cases over a 2-week period rose more than 100% in most of Europe, Africa and the Americas. However, in countries with robust vaccine programs, the 2-week daily averages of new hospitalizations and deaths rose at much smaller rates, usually less than 50%.

Most vaccines used around the world, including the Pfizer, Moderna and Johnson & Johnson vaccines approved in the US, have shown significant protection against severe symptoms from the Delta variant. Though the Delta variant has caused breakthrough infections in vaccinated people at a higher rate than other variants, that number still amounts to less than 1% of all vaccinated people. Worldwide, almost all hospitalizations and deaths since June 1 have occurred among non-vaccinated people.